Genetically low vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Afzal, Shoaib ^a,b   Brøndum Jacobsen, Peter ^a,b   Bojesen, Stig E ^a,b,c   Nordestgaard, Børge G ^a,b,c  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D; CALCIFEDIOL;

ADULT; AGED; ALLELE; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; GENETIC VARIABILITY; GENOTYPE; HEALTH STATUS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MENDELIAN RANDOMIZATION ANALYSIS; MORTALITY; RISK FACTOR; SCORING SYSTEM; SENSITIVITY ANALYSIS; VERY ELDERLY; WORLD HEALTH ORGANIZATION; BLOOD; CARDIOVASCULAR DISEASE; CAUSALITY; DEFICIENCY; EPIDEMIOLOGY; GENE FREQUENCY; GENETICS; NEOPLASM; VITAMIN D DEFICIENCY;

CALCIFEDIOL; CARDIOVASCULAR DISEASES; CAUSALITY; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); GENE FREQUENCY; GENOTYPE; HUMANS; MENDELIAN RANDOMIZATION ANALYSIS; NEOPLASMS; VITAMIN D DEFICIENCY;

EID: 84911429837     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g6330     Document Type: Article

References (55)

1. Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury S, Kiefte-de-Jong JC, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ 2014;348:g1903.
2. Schottker B, Jorde R, Peasey A, Thorand B, Jansen EH, Groot L, et al. Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. BMJ 2014;348:g3656.
3. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2014;1:CD007470.
4. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004;33:30-42.
5. Lawlor D.A., Harbord RM, Sterne JA, Timpson N, Davey SG. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27:1133-63.
6. Afzal S, Brondum-Jacobsen P, Bojesen SE, Nordestgaard BG. Vitamin D concentration, obesity, and risk of diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol 2014;2:298-306.
7. Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 2010;19):2739-45.
8. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010;376:180-8.
9. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34:3478-90a.
10. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
11. Andersen RV, Wittrup HH, Tybjaerg-Hansen A, Steffensen R, Schnohr P, Nordestgaard BG. Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study. J Am Coll Cardiol 2003;41:1972-82.
12. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008;299:2524-32.
13. Haase CL, Tybjaerg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab 2012;97:E248-56.
14. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572-80.
15. Di AE, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
16. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.
17. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99.
18. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67.
19. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-91.
20. Nordestgaard BG, Palmer TM, Benn M, Zacho J, Tybjaerg-Hansen A, Davey SG, et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a mendelian randomisation approach. PLoS Med 2012;9:e1001212.
21. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-908.
22. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013;369:1991-2000.
23. Burgess S, Thompson SG. Use of allele scores as instrumental variables for mendelian randomization. Int J Epidemiol 2013;42:1134-44.
24. Ala Alwan (ed). Global status report on noncommunicable diseases 2010. World Health Organization, 2011 (available at www.who.int/nmh/publications/ncd-report-full-en.pdf).
25. Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health 2011;39(7 suppl):26-9.
26. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792-802.
27. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999;150:341-53.
28. Afzal S, Nordestgaard BG, Bojesen SE. Plasma 25-hydroxyvitamin D and risk of non-melanoma and melanoma skin cancer: a prospective cohort study. J Invest Dermatol 2013;133:629-36.
29. Thomas DC, Lawlor D.A., Thompson JR. Re: Estimation of bias in nongenetic observational studies using "mendelian triangulation" by Bautista, et al. Ann Epidemiol 2007;17:511-3.
30. Didelez V, Meng S, Sheehan NA. Assumptions of IV methods for observational epidemiology. Stat Sci 2010;25:22-40.
31. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
32. Manson JE, Bassuk SS, Lee IM, Cook NR, Albert M.A., Gordon D, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012;33:159-71.
33. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 2014;348:g2035.
34. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010;28:1248-50.
35. The Human Protein Atlas. VDR. 2013. www.proteinatlas.org/ENSG00000111424/tissue.
36. The Human Protein Atlas. CYP2R1. 2013. www.proteinatlas.org/ENSG00000186104/tissue.
37. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 2010;20:1352-60.
38. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
39. Eisman JA, Barkla DH, Tutton PJ. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res 1987;47:21-5.
40. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996;10:142-53.
41. Ordonez-Moran P, Larriba MJ, Pendas-Franco N, Aguilera O, Gonzalez-Sancho JM, Munoz A. Vitamin D and cancer: an update of in vitro and in vivo data. Front Biosci 2005;10:2723-49.
42. Shabahang M, Buras RR, Davoodi F, Schumaker LM, Nauta RJ, Evans SR. 1,25-dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 1993;53:3712-8.
43. Simboli-Campbell M, Narvaez CJ, Tenniswood M, Welsh J. 1,25-dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 1996;58:367-76.
44. Bouillon R, Carmeliet G, Verlinden L, van EE, Verstuyf A, Luderer HF, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008;29:726-76.
45. Keisala T, Minasyan A, Lou YR, Zou J, Kalueff AV, Pyykko I, et al. Premature aging in vitamin D receptor mutant mice. J Steroid Biochem Mol Biol 2009;115:91-7.
46. Levin GP, Robinson-Cohen C, de Boer IH, Houston DK, Lohman K, Liu Y, et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA 2012;308:1898-905.
47. Trummer O, Pilz S, Hoffmann MM, Winkelmann BR, Boehm BO, Marz W, et al. Vitamin D and mortality: a mendelian randomization study. Clin Chem 2013;59:793-7.
48. Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, et al. Causal relationship between obesity and vitamin D status: bi-directional mendelian randomization analysis of multiple cohorts. PLoS Med 2013;10:e1001383.
49. Ooi EM, Afzal S, Nordestgaard BG. Elevated remnant cholesterol in 25-hydroxyvitamin D deficiency in the general population: a mendelian randomization study. Circ Cardiovasc Genet 2014; published online 27 July.
50. Berry DJ, Vimaleswaran KS, Whittaker JC, Hingorani AD, Hypponen E. Evaluation of genetic markers as instruments for mendelian randomization studies on vitamin D. PLoS One 2012;7:e37465.
51. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in mendelian randomization studies. Int J Epidemiol 2013;42:1497-501.
52. Tetens I, Biltoft-Jensen A, Spagner C, Christensen T, Gille MB, Bugel S, et al. Intake of micronutrients among Danish adult users and non-users of dietary supplements. Food Nutr Res 2011;55:doi:10.3402/fnr.v55i0.7153.
53. Afzal S, Bojesen SE, Nordestgaard BG. Low 25-hydroxyvitamin D and risk of type 2 diabetes: a prospective cohort study and metaanalysis. Clin Chem 2013;59:381-91.
54. Rode L, Bojesen SE, Weischer M, Nordestgaard BG. High tobacco consumption is causally associated with increased all-cause mortality in a general population sample of 55 568 individuals, but not with short telomeres: a mendelian randomization study. Int J Epidemiol 2014;43:1473-83.
55. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013;61:427-36.